1 Organized by: School of Pharmacy Co-organized by: Pusat Penelitian Nanosains dan Nanoteknologi Sponsored by: i COMMITTEE: Steering Committee □ Prof. Dr. Daryono Hadi Tjahjono, M.Sc. (Dean, School of Pharmacy ITB Indonesia) □ Prof. Dr. Slamet Ibrahim (Chairman of Senat of School of Pharmacy ITB Indonesia) □ Prof. Dr. Debbie Sofie Retnoningrum (Chairman of Pharmaceutics Research Group, School of Pharmacy ITB Indonesia) □ Prof. Dr. Irda Fidrianny (Chairman of Pharmaceutical Biology Research Group School of Pharmacy ITB, Indonesia) □ Prof. Dr. I Ketut Adnyana (Chairman of Pharmacology and Clinical Pharmacy Research Group School of Pharmacy ITB, Indonesia) □ Prof. Dr. Andreanus A Soemardji (School of Pharmacy ITB, Indonesia) □ Prof. Dr. Elin Yulinah S (School of Pharmacy ITB, Indonesia) □ Prof. Dr. Sukmadjaja Asyarie (School of Pharmacy ITB, Indonesia) □ Prof. Dr. Yeyet Cahyati S (School of Pharmacy ITB, Indonesia) □ Prof. Dr. Sundani Nurono Soewandhi (School of Pharmacy ITB, Indonesia) □ Prof. Dr. Jessie Sofia Pamudji (School of Pharmacy ITB, Indonesia) □ Prof. Dr. Komar Ruslan Wirasutisna (School of Pharmacy ITB, Indonesia) □ Prof. Dr. Asep Gana Suganda (School of Pharmacy ITB, Indonesia) □ Prof. Dr. Sukrasno (School of Pharmacy ITB, Indonesia) □ Prof. Hideyoshi Harashima (Hokkaido University) □ Dr. Sci. Hidehiro Uekusa (Tokyo Institute of Technology) □ Prof. Federico Gago (University of Alcalá) □ dr. Matjis van Meurs (University of Groningen) □ Prof. Dr. Wim. J. Quax (University of Groningen) □ Prof Maria Jose Alonso (CIMUS Research Center, Santago de Compostela, Spain) Organizing Committee Chairman Dr. Rachmat Mauludin Team Dr. Ratna Annisa Utami Dr. Yuda Prasetya Nugraha Eskarani Tri Pratiwi M. Farm Muhamad Fahmi Hasan, M.Or Dr. Catur Riani Dr. Pratiwi Wikaningtyas Dr. Amirah Adlia Dr. Fransiska Kurniawan Dr. Ilma Nugrahani Agung Dwi Juniarsyah M.Or Dr. Aluicia Anita Artarini Iwa Ikhwan Hidayat M.Or Anis Susieyeni M.Ds Sri Indah Ihsani M.Or Bhekti Pratiwi M.Si., Apt Dr. Muhamad Insanu Dr. Afrillia Nuryanti G Dhyan Kusuma Ayuningtyas M.Si Nur Azizah Fitria M.Sc Muhamad Azhari M.Si Dr. Benny Permana Hubbi Nashrullah M.Si i Editor □ Prof. Dr. Daryono Hadi Tjahjono, M.Sc. (Dean, School of Pharmacy ITB Indonesia) □ Prof. Dr. Slamet Ibrahim (Chairman of Senat of School of Pharmacy ITB Indonesia) □ Prof. Dr. Debbie Sofie Retnoningrum (Chairman of Pharmaceutics Research Group, School of Pharmacy ITB Indonesia) □ Prof. Dr. Irda Fidrianny (Chairman of Pharmaceutical Biology Research Group School of Pharmacy ITB, Indonesia) □ Prof. Dr. I Ketut Adnyana (Chairman of Pharmacology and Clinical Pharmacy Research Group School of Pharmacy ITB, Indonesia) □ Prof. Dr. Andreanus A Soemardji (School of Pharmacy ITB, Indonesia) □ Prof. Dr. Elin Yulinah S (School of Pharmacy ITB, Indonesia) □ Prof. Dr. Sukmadjaja Asyarie (School of Pharmacy ITB, Indonesia) □ Prof. Dr. Yeyet Cahyati S (School of Pharmacy ITB, Indonesia) □ Prof. Dr. Sundani Nurono Soewandhi (School of Pharmacy ITB, Indonesia) □ Prof. Dr. Jessie Sofia Pamudji (School of Pharmacy ITB, Indonesia) □ Prof. Dr. Komar Ruslan Wirasutisna (School of Pharmacy ITB, Indonesia) □ Prof. Dr. Asep Gana Suganda (School of Pharmacy ITB, Indonesia) □ Prof. Dr. Sukrasno (School of Pharmacy ITB, Indonesia) □ Dr. Lucy Dewi Nurhajati Sasongko (School of Pharmacy ITB, Indonesia) □ Dr.rer.nat Rahmana Emran Kartasasmita (School of Pharmacy ITB, Indonesia) □ Prof. Dr. Heni Rachmawati (School of Pharmacy ITB, Indonesia) □ Dr. Muhamad Insanu (School of Pharmacy ITB, Indonesia) □ Dr. Neng Fisheri Kurniati (School of Pharmacy ITB, Indonesia) □ Prof. Hideyoshi Harashima (Hokkaido University) □ Dr. Sci. Hidehiro Uekusa (Tokyo Institute of Technology) □ Prof. Federico Gago (University of Alcalá) □ dr. Matjis van Meurs (University of Groningen) □ Prof. Dr. Wim. J. Quax (University of Groningen) □ Prof Maria Jose Alonso (CIMUS Research Center, Santago de Compostela, Spain) ii TABLE OF CONTENTS: Welcome Address from Rector ITB vii OP-3 In Vitro Micropropagation of Welcome Remarks by the Chairman of Two Varieties of Orthosiphon 1st ITB ICPSP 2020 ……………………………. viii aristatus Blume Miq …………… 15 OP-4 EVALUATION of CD4 COUNT Schedule Day 1 ………………..……………….. Ix IN HIV OUTPATIENTS WITH Schedule Day 2 ………………..……………….. x OPPORTUNISTIC INFECTION (A Retrospective Study) ……… 16 OP-5 THE CORRELATION OF SPEAKER HBA1C WITH SPUTUM Multifunctional Envelope-type Nano CONVERSION IN Device for gene delivery: Concept and TUBERCULOSIS PATIENTS Clinical Application for Nanomedicine 2 CATEGORY I WITH DIABETES Pharmaceutical Co-crystals - Crystal MELLITUS (A Cohort Structure and Property Relationship…. 3 Prospective Study) …………….. 17 Molecular modeling and computer OP-6 IN VITRO BIOLOGICAL simulations ………………..…………………….. 4 ACTIVITIES OF METHANOL Novel drugtargets for Acute Kidney EXTRACT OF DIPLAZIUM Injury ………………..………………..…………… 5 ESCULENTUM LEAVES Design and development of novel (ANTIOXIDANT, nanostructures as drug delivery ANTIDIABETIC AND carriers ………………..………………………….. 6 TOXICITY) …………………………… 18 Engineering TNF-ligand Family OP-7 Alpha Glucosidase Inhibition Members for Future Therapies ……….. 7 of Crude Ethanol Extract and Fraction of Kedabu Fruit Salt-cocrystallization as a strategy to (Sonneratia ovata Backer)…. 19 improve the drug’s physicochemical OP-8 Improved insulin sensitivity properties: can a cocrystal be with extract and Active generated from salt compound? ……… 8 fractions of Hibiscus Development of Medicinal Plants surattensis L. leaves in Using Biotechnological Approaches …. 9 diabetic mice ………………… 20 Neuroinflammation and Addictive OP-9 Effects of 2- (3- Drug Dependence ………………..…………… 10 (chloromethyl)benzoyloxy)b Surface Modification of Lipid enzoic acid on TNF-α and IL- Nanoparticle to Improve Antibiotic 1β Cytokines Levels in Cellular Uptake ………………..……………….. 11 Lipopolysaccharide-Induced Rat …………………………………… 21 OP-10 Effects of 2- (4- ORAL PRESENTATION (chloromethyl)benzoyloxy)b OP-1 ANTIOXIDANT ACTIVITIES enzoic acid on TNF-α and IL- AND TOTAL PHENOL FROM 1β Cytokines Levels in MARINE MICROALGAE Lipopolysaccharide-Induced Chlorella vulgaris ……………….. 13 Rat ………… ………………………. 22 OP-2 Optimization of Ultrasound- OP-11 EFFECT OF 2-((3- assisted Deep Eutectic (CHLOROMETHYL)BENZOYL) Solvent Extraction of OXY)BENZOIC ACID Phenolic Compounds from COMPOUND ON THE Ixora javanica Flowers ……… 14 DEGREE OF INFLAMMATION OF LUNG AND LIVER OF iii LIPOPOLYSACCHARIDES- OP-21 Effectivity of Gel Form of INDUCED MALE WISTAR Ricinus communis L Leaves RATS ………………………………… 23 Extract Against Burns OP-12 Effect Of 2-(4- Healing of Rat Model ……… 33 (Chloromethyl)Benzoyloxy)B OP-22 ANTIBACTERIAL ACTIVITY OF enzoic Acid Compound On ESSENTIAL OILS OF POMELO The Degree Of Inflammation PEEL (Citrus maxima) Of Lung And Liver Organs In AGAINST BACTERIAL Lipopolysaccharides-Induced CAUSING BODY ODOR Wistar Rats …………… ………… 24 (Staphylococcus epidermidis) 34 OP-13 MANURAN’S ROOT OP-23 Red Ginger Nutraceutical (Captosapelta tomentosa Nanoparticles as Pain Relief Valeton ex K. Heyne) AS in Menstruation APHRODISIAC ON WHITE (Dysmenorrhea) ……………….. 35 MALE MICE (Mus musculus OP-24 GPCR Receptor (D2 L) …………… …………… …………… 25 Receptor) Related by OP-14 Budesonide treatment does Nicotine-Induced not prevent airway Conditioned Preference neuroplasticity in a murine Through Calcium Calmodulin chronic asthma model ……… 26 Protein Dependent Kinase OP-15 Acute Toxicity Assessment of (CaMKII) and Extracellular- “Bitter Honey” (Alstonia Signal Regulated Kinase scholaris) and (ERK) the Promising Target Histopathology Images in for Nicotine Dependence Mice (Mus musculus) ………… 27 Therapy.……………………………. 36 OP-16 Antihypertensive activity of OP-25 Analysis of Physical- cucumber fruit (Cucumis Chemical, Toxicology and sativus L.) in hypertensive Target Potential of Pure rats induced by Compounds from Andalas dexamethasone ……………….. 28 Sitawa Fitolab: A OP-17 Traditional Medicinal Plants Computational Study ………… 37 used for Lowering Blood OP-26 In Silico Studies of Several Pressure: Mode of action Compounds of Peperomia and their interaction with pellucida (L.) Kunth. standard antihypertensive Targeting Cathepsin K and agents …………… ………………. 29 MMP-9 for Osteoporosis OP-18 Antihypertensive activity of Treatment ………………………… 38 cucumber fruit (Cucumis OP-27 QUANTITATIVE STRUCTURE- sativus L.) in hypertensive ACTIVITY RELATIONSHIP OF rats induced by adrenaline … 30 4-(3-NITROPHENYL)- OP-19 Antihypertensive activity of THIAZOL-2-YLHYDRAZONE AS cucumber fruit (Cucumis INHIBITOR OF MONOAMINE sativus L.) in hypertensive OXIDASE B ENZYMES FOR rats induced by angiotensin THE TREATMENT OF II …………… …………… …………… 31 PARKINSON'S DISEASE ……… 39 OP-20 EFFECT OF BLACK GARLIC OP-28 Molecular Docking, 3D (Allium sativum (L)) TO Structure-Based REDUCTION OF TOTAL Pharmacophore Modelling, CHOLESTEROL LEVELS IN and ADMET Prediction of WHITE MALE MICE …………… 32 Amentoflavone against the ii Main Protease of SARS-CoV- 40 OP-38 Optimization and Evaluation 2 ……………………………………… of Alginate-HPMC OP-29 Esterification of Cinchonine Microspheres Composition Alkaloid and Anticancer for Encapsulation of Activity Test Against MCF-7 Bromelain as Antiplatelet …. 50 Breast Cancer Cells …………… 41 OP-39 Nanosuspension OP-30 New HPLC Method for Formulation of Ethanol Concomitant Quantification Extract of Safflower’s of Doxycycline, Ivermectine (Carthamus tinctorius L.) …… 51 and Albendazole Metabolites OP-40 Mouthwash Formulation and in Rat Plasma Following Evaluation of Bundung Plants Simulatenous Oral (Actinoscirpus grossus) Administration